BioCentury | Apr 17, 2021
Deals

April 16 Quick Takes: AZ’s $39B Alexion deal clears FTC hurdle; plus Biosplice, C2i, Relay, Surrozen and more

...Management and Lauxera Capital Partners to expand R&D and commercialization of z-Movi Cell Avidity Analyzer. Softbank...
BioCentury | Apr 14, 2021
Deals

April 13 Quick Takes: Mega-rounds for Flagship's Repertoire, Arcellx, GH, Theseus; plus Biophytis, Resilience, Cerevel, C4X, Sanofi and more

...million in a series B financing from founding investor Flagship Pioneering and other investors including Softbank...
BioCentury | Mar 30, 2021
Deals

March 29 Quick Takes: SPAC carrying SomaLogic to NASDAQ; plus LianBio-Tarsus, Qihan, Biohaven, Tempest

...Investors in the deal include Casdin, Corvex, Janus Henderson Investors, SB Management, a subsidiary of SoftBank...
BioCentury | Mar 16, 2021
Deals

March 15 Quick Takes: Canada’s CPP leads insitro’s $400M series C; plus Bicara, Aveo, Gilead-Merck and more

...series B closed in May 2020. Also backing the machine learning-guided drug discovery company were Temasek, Softbank...
BioCentury | Mar 15, 2021
Finance

Cell and gene therapy accelerator ElevateBio continues to refine ‘sweet spot’ with $525M series C

...these innovative medicines to a broader population in a more affordable fashion,” said Finer. New investors SoftBank...
...Ventures, iTochu and a large insurance company. In conjunction with the financing, Matrix’s Karan Takhar and SoftBank’s...
BioCentury | Feb 25, 2021
Finance

$135M series C buys Vividion flexibility to explore broad pipeline

...of which re-upped in the new round. Another new investor of note is SoftBank Investment Advisers. Softbank...
...gene writing play Tessera Therapeutics Inc., co-led by SoftBank Vision Fund 2i. In another recent investment, SoftBank...
BioCentury | Feb 11, 2021
Product Development

Feb. 10 Quick Takes: Softly goes PacBio; plus PGDx, Nuvation Bio, Gamida, Portal Innovations

...By BioCentury Staff Softbank Group Corp.’s SB Management unit is investing $900 million in Pacific Biosciences of...
BioCentury | Jan 13, 2021
Deals

Jan. 12 Quick Takes: $230M series B for Flagship’s ‘gene writer’ Tessera; plus Elucida, Vedanta, AbbVie-Dragonfly, Primmune

...million series B round co-led by Alaska Permanent Fund Corporation, Altitude Life Science Ventures and SoftBank...
BioCentury | Dec 10, 2020
Finance

Dec. 9 Quick Takes: Nuance leads bolus of venture rounds for China’s innovators; plus launches for Hillhouse’s Overland, OSI’s PepGen and Atlas’ Vigil and more

...offices in Shanghai, Beijing and Boston, has yet to disclose details on its funding and pipeline.SoftBank...
...play Pear Pear Therapeutics Inc. raised $80 million in a series D financing led by SoftBank...
BioCentury | Dec 5, 2020
Finance

Seer posts triple-digit gain as trio of new listings adds to 2020’s record NASDAQ haul

...a valuation of almost $3.3 billion.A $135 million private investment by Fidelity, T. Rowe Price, SoftBank...
Items per page:
1 - 10 of 70
BioCentury | Apr 17, 2021
Deals

April 16 Quick Takes: AZ’s $39B Alexion deal clears FTC hurdle; plus Biosplice, C2i, Relay, Surrozen and more

...Management and Lauxera Capital Partners to expand R&D and commercialization of z-Movi Cell Avidity Analyzer. Softbank...
BioCentury | Apr 14, 2021
Deals

April 13 Quick Takes: Mega-rounds for Flagship's Repertoire, Arcellx, GH, Theseus; plus Biophytis, Resilience, Cerevel, C4X, Sanofi and more

...million in a series B financing from founding investor Flagship Pioneering and other investors including Softbank...
BioCentury | Mar 30, 2021
Deals

March 29 Quick Takes: SPAC carrying SomaLogic to NASDAQ; plus LianBio-Tarsus, Qihan, Biohaven, Tempest

...Investors in the deal include Casdin, Corvex, Janus Henderson Investors, SB Management, a subsidiary of SoftBank...
BioCentury | Mar 16, 2021
Deals

March 15 Quick Takes: Canada’s CPP leads insitro’s $400M series C; plus Bicara, Aveo, Gilead-Merck and more

...series B closed in May 2020. Also backing the machine learning-guided drug discovery company were Temasek, Softbank...
BioCentury | Mar 15, 2021
Finance

Cell and gene therapy accelerator ElevateBio continues to refine ‘sweet spot’ with $525M series C

...these innovative medicines to a broader population in a more affordable fashion,” said Finer. New investors SoftBank...
...Ventures, iTochu and a large insurance company. In conjunction with the financing, Matrix’s Karan Takhar and SoftBank’s...
BioCentury | Feb 25, 2021
Finance

$135M series C buys Vividion flexibility to explore broad pipeline

...of which re-upped in the new round. Another new investor of note is SoftBank Investment Advisers. Softbank...
...gene writing play Tessera Therapeutics Inc., co-led by SoftBank Vision Fund 2i. In another recent investment, SoftBank...
BioCentury | Feb 11, 2021
Product Development

Feb. 10 Quick Takes: Softly goes PacBio; plus PGDx, Nuvation Bio, Gamida, Portal Innovations

...By BioCentury Staff Softbank Group Corp.’s SB Management unit is investing $900 million in Pacific Biosciences of...
BioCentury | Jan 13, 2021
Deals

Jan. 12 Quick Takes: $230M series B for Flagship’s ‘gene writer’ Tessera; plus Elucida, Vedanta, AbbVie-Dragonfly, Primmune

...million series B round co-led by Alaska Permanent Fund Corporation, Altitude Life Science Ventures and SoftBank...
BioCentury | Dec 10, 2020
Finance

Dec. 9 Quick Takes: Nuance leads bolus of venture rounds for China’s innovators; plus launches for Hillhouse’s Overland, OSI’s PepGen and Atlas’ Vigil and more

...offices in Shanghai, Beijing and Boston, has yet to disclose details on its funding and pipeline.SoftBank...
...play Pear Pear Therapeutics Inc. raised $80 million in a series D financing led by SoftBank...
BioCentury | Dec 5, 2020
Finance

Seer posts triple-digit gain as trio of new listings adds to 2020’s record NASDAQ haul

...a valuation of almost $3.3 billion.A $135 million private investment by Fidelity, T. Rowe Price, SoftBank...
Items per page:
1 - 10 of 70